Showing results (101-110 of 113) with videos related to
Sort By:
Pageof 12
The Pediatric Infectious Disease Journal|December 23, 2024
Clinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive SummaryYoshinori Ito, Takuya Yamagishi, Chiaki Ikenoue, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 5, 2020
Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: General overview of pathogenic antimicrobial susceptibilityNaruhiko Ishiwada, Kazuo Fujimaki, Tetsuya Matsumoto, et al.European Journal of Human Genetics : EJHG|September 16, 2004
CD40 ligand gene and Kawasaki diseaseYoshihiro Onouchi, Sakura Onoue, Mayumi Tamari, et al.Microbiology and Immunology|January 9, 2025
Genome Analysis of Japanese Yersinia pseudotuberculosis Strains Isolated From Kawasaki Disease Patients and Other Sources and Their Phylogenetic Positions in the Global Y. pseudotuberculosis PopulationKazuaki Yasuoka, Yasuhiro Gotoh, Itsuki Taniguchi, et al.The Pediatric Infectious Disease Journal|February 2, 2023
Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in JapanTomohiro Katsuta, Yuta Aizawa, Kensuke Shoji, et al.Nature Genetics|December 18, 2007
ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysmsYoshihiro Onouchi, Tomohiko Gunji, Jane C Burns, et al.Pediatrics International : Official Journal of the Japan Pediatric Society|July 7, 2021
The clinical characteristics of pediatric coronavirus disease 2019 in 2020 in JapanTomohiro Katsuta, Naoki Shimizu, Kenji Okada, et al.The Pediatric Infectious Disease Journal|August 11, 2023
Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan 2022Naruhiko Ishiwada, Masayoshi Shinjoh, Yoshiki Kusama, et al.Lancet (London, England)|March 12, 2019
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trialHiromichi Hamada, Hiroyuki Suzuki, Yoshihiro Onouchi, et al.Human Molecular Genetics|April 29, 2010
Common variants in CASP3 confer susceptibility to Kawasaki diseaseYoshihiro Onouchi, Kouichi Ozaki, Jane C Buns, et al.Pageof 12